Rekrutierende Studien
AARON
An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients
MOSAIC
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
PEMAZA
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse
VENAZA-5S
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment- naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy